Vasopressin and shock

Anaesthesia and Intensive Care

Volumn 29, Issue 5, 2001, Pages 463-472

  Forrest, P ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Mechanism of action; Pharmacology: vasopressin; Shock

Indexed keywords

ADRENALIN; CATECHOLAMINE; DESMOPRESSIN; NORADRENALIN; PLACEBO; VASOPRESSIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASYSTOLE; BLOOD FLOW; BRAIN; BRONCHOSPASM; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG MECHANISM; DRUG USE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HORMONE ACTION; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOVOLEMIA; INJECTION SITE; INTESTINE ISCHEMIA; MEDICAL INFORMATION; MEDICAL LITERATURE; RASH; REVIEW; SEPSIS; SHOCK; SIDE EFFECT; SWINE; URTICARIA; VASOCONSTRICTION; VASODILATATION; VEIN THROMBOSIS;

EID: 0034767565     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0102900503     Document Type: Review

References (97)

1. Vasopressin and other agents affecting the renal conservation of water
2. The pressor effect of the anti-diuretic principle of the posterior pituitary in orthostatic hypotension
3. Blood pressure in acute and chronic vasopressin excess
4. Stress hormone response during and after cardiopulmonary resuscitation
5. Renal excretion of antidiuretic hormone in healthy subjects and patients with renal failure
6. Role of peripheral receptors in the increased release of vasopressin in response to hemorrhage
7. Vasopressin release during sepsis and septic shock in baboons and dogs
8. Hemodynamic and metabolic effects of vasopressin blockade in endotoxin shock
9. Neuroendocrine activation after acute myocardial infarction
10. Clinical and hemodynamic correlates of elevated plasma arginine vasopressin levels after acute myocardial infarction
11. Plasma vasopressin levels in during cardiopulmonary bypass with and without profound hemodilution
12. Plasma vasopressin levels and urinary sodium excretion during cardiopulmonary bypass with and without pulsatile flow
13. Endogenous vasopressin and renin-angiotensin systems support blood pressure after epidural block in humans
14. Vasopressin and angiotensin II in blood pressure control during isoflurane anesthesia in rats
15. Vasopressin and anesthesia, surgery
16. Endogenous vasopressin release modifies the cardiovascular response to exercise
17. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock
18. The secretion and clearance of vasopressin during the development of irreversible hemorrhagic shock
19. Vasopressin deficiency contributes to the vasodilation of septic shock
20. A prospective randomised trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement
21. Management of vasodilatory shock after cardiac surgery: Identification of pre-disposing factors and use of a novel pressor agent
22. Comparison of the effects of water deprivation and sodium chloride imbibation on the hormone content of the neurohypophysis of the rat
23. Reversible vasopressin deficiency in severe hyponatraemia
24. Vasopressin response to orthostatic hypotension: Etiologic and clinical implications
25. Plasma endothelin during upright tilt: Relevance for orthostatic hypotension?
26. Spectral analysis of heart rate variability in the sepsis syndrome
27. Central nervous system function after cardiopulmonary bypass
28. Influence of cardiopulmonary bypass, temperature, cardioplegia and topical hypothermia on cardiac innervation
29. Vasopressin and hypertension in man
30. Urinary and metabolic clearances of arginine vasopressin in normal subjects
31. Vasopressin pressor hypersensitivity in vasodilatory septic shock
32. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs
33. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo
34. Role of nitric oxide in the cerebral vasodilatory responses to vasopressin and oxytocin in dogs
35. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery
36. Vasopressin in cardiovascular control: Role of circulating vasopressin
37. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide
38. Vasoconstrictor role for vasopressin in experimental heart failure
39. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure
40. Direct cardiac effects of vasopressin: Role of V1- and V2-vasopressinergic receptors
41. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man
42. Hemodynamic effects of infused arginine vasopressin in congestive heart failure
43. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist
44. Circulatory actions of vasopressin in anaesthetised rats with portal hypertension subjected to haemorrhage
45. Effects of vasopressin on portal hemodynamics in patients with portal hypertension
46. High-dose vasopressin for acute variceal hemorrhage. Clinical advantages without adverse effects
47. Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension
48. Lack of vasopressin action on splanchnic hemodynamics during bleeding: A study in conscious, portal hypertensive rats
49. Vascular vasopressin receptors
50. Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney
51. Regional differences in the arterial response to vasopressin: Role of nitric oxide
52. Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin
53. Vasopressin modulates K-channel activities of cultured smooth muscle cells from porcine coronary artery
54. + channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dogs
55. ATP-channel inhibition improves hemodynamics and cellular energies in hemorrhagic shock
56. Arginine vasopressin inhibits interleukin-1-β-stimulated nitric oxide production via the V1 receptor in cultured rat vascular smooth muscle
57. Inflammatory cells and mediators in the silicon chamber model for nerve regeneration
58. Cytokine and anti-cytokine strategies in inflammatory reaction modulation
59. Renal microvascular effects of vasopressin and vasopressin antagonist
60. Coronary vasoconstriction produced by vasopressin in anesthetised goats. Role of vasopressin V1 and V2 receptors and nitric oxide
61. Enhanced renal vasoconstrictor responsiveness to vasopressin after renal denervation
62. Metabolic clearance rate of immunoreactive vasopressin in man
63. Distribution, blood transport and degradation of antidiuretic hormone in man
64. Metabolic clearance rate of arginine vasopressin in severe chronic renal failure
65. Metabolic clearance rate of arginine vasopressin in patients with cirrhosis
66. High dose and standard dose adrenaline do not alter survival, compared with placebo, in cardiac arrest
67. A randomised clinical trial of high-dose epinephrine and norepinephrine vs. standard-dose epinephrine in prehospital cardiac arrest
68. High dose epinephrine in cardiac arrest
69. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital
70. Beta-adrenergic blockade reduces myocardial injury during experimental cardiopulmonary resuscitation
71. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with post-countershock pulseless electrical activity in pigs
72. Survival with full neurologic recovery and no cerebral pathology after prolonged cardiopulmonary resuscitation with vasopressin in pigs
73. Synergistic effects of vasopressin plus epinephrine during cardiopulmonary resuscitation
74. Cardiopulmonary resuscitation during severe hypothermia in pigs: Does epinephrine or vasopressin increase coronary perfusion pressure?
75. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs
76. Endobronchial vasopressin improves survival during cardiopulmonary resuscitation in pigs
77. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation
78. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation
79. Vasopressin and endothelin release during cardiopulmonary resuscitation
80. Introduction to ACLS 2000: Overview of recommended changes to the ACLS from the Guidelines 2000 conference
81. Prehospital traumatic cardiac arrest: The cost of futility
82. Outcomes of trauma patients with no vital signs on hospital admission
83. Efficacy of cardiopulmonary resuscitation in pulseless pediatric trauma patients
84. Guidelines for cardiopulmonary resuscitation and emergency cardiac care
85. European Resuscitation Council guidelines for adult advanced cardiac life support, and approved by the executive committee of the European Resuscitation Council
86. Vasopressin improves survival after cardiac arrest in hypovolemic shock
87. High-dose epinephrine results in greater early mortality after resuscitation from prolonged cardiac arrest in pigs: A prospective, randomised study
88. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilisation in hyperdynamic sepsis
89. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism and gastric tonometric variables in septic shock: A prospective, randomised study
90. Pharmacologic manipulation of the peripheral vasculature in shock. Clinical and experimental approaches
91. Reversal of intractable septic shock with norepinephrine therapy
92. Low-dose vasopressin in the treatment of vasodilatory septic shock
93. Vasopressin for refractory hypotension during cardiopulmonary bypass
94. Vasopressin for the treatment of refractory hypotension after cardiopulmonary bypass
95. Hypothalamic and Pituitary Hormones